Chengdu Jianze Pharmaceutical Technology

Chengdu Jianze Pharmaceutical Technology is a Chinese biotechnology company dedicated to addressing the unmet clinical needs of rare disease patients by developing affordable orphan drugs. The company primarily focuses on the neurological field, with its lead program being Taltirelin tablets, a thyrotropin-releasing hormone receptor (TRHR) agonist currently undergoing bioequivalence clinical trials for the treatment of spinocerebellar degeneration. Beyond drug development, Chengdu Jianze integrates patient care through its 'Patient Community Peer' initiative, providing personalized cognitive, medication, and rehabilitation management. Based in Chengdu, China, the company aims to deliver high-quality, accessible therapeutic solutions for chronic rare diseases.